Values First Advisors’s Celldex Therapeutics CLDX Stock Holding History

Values First Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$340K	Buy	+10,483	New	+$401K	0.16%	136
2026 Q1	–	Sell	-7,728	Closed	-$210K	–	183
2025 Q4	$210K	Buy	+7,728	New	+$204K	0.11%	163
2025 Q2	–	Sell	-29,933	Closed	-$550K	–	186
2025 Q1	$550K	Buy	29,933 +924	+3%	+$20.6K	0.32%	83
2024 Q4	$733K	Buy	29,009 +4,837	+20%	+$131K	0.4%	70
2024 Q3	$822K	Buy	24,172 +2,853	+13%	+$109K	0.45%	63
2024 Q2	$789K	Buy	21,319 +1,627	+8%	+$61.4K	0.47%	60
2024 Q1	$826K	Buy	19,692 +12,293	+166%	+$505K	0.48%	60
2023 Q4	$293K	Buy	+7,399	New	+$218K	0.18%	130
2023 Q3	–	Sell	-7,560	Closed	-$257K	–	166
2023 Q2	$257K	Buy	7,560 +2,258	+43%	+$76.1K	0.15%	139
2023 Q1	$191K	Sell	5,302 -2,238	-30%	-$96.6K	0.12%	142
2022 Q4	$336K	Buy	+7,540	New	+$269K	0.23%	111

Other funds holding CLDX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

TSP Capital Management Group Summit, New Jersey $397M AUM 31.23% 1-Year Est. Return

Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $620M AUM 38.17% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Apella Capital West Hartford, Connecticut $7.88B AUM 10.78% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Overbrook Management Corp New York $643M AUM 29.06% 1-Year Est. Return

Values First Advisors's CLDX Position: Q3 2026 in Review

Values First Advisors opened a new position in Celldex Therapeutics (CLDX) in Q3 2026: 10,483 shares worth $340K. The stake represents 0.16% of the portfolio and ranks #136 among its holdings. This is a return to the name: Values First Advisors previously reported a position in CLDX as recently as Q4 2025.

Values First Advisors first reported a position in CLDX in Q4 2022 and has held it in 11 quarters since. The position peaked at $826K in Q1 2024. 41 funds tracked by Wall St. Rank hold CLDX as of Q3 2026.

Values First Advisors held 10,483 shares of Celldex Therapeutics worth $340K as of Q3 2026.
Celldex Therapeutics was a new Values First Advisors position in Q3 2026.
Celldex Therapeutics made up 0.16% of Values First Advisors's portfolio in Q3 2026, its #136 holding.
Values First Advisors first reported a position in Celldex Therapeutics in Q4 2022 and has held it in 11 quarters since.
Values First Advisors's Celldex Therapeutics position peaked at $826K in Q1 2024.
41 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2026.

Based on Values First Advisors's 13F filing for Q3 2026, filed 23 Oct 2026.